New first-line immunotherapy plus TKI combinations for metastatic kidney cancer
Approval of axitinib plus pembrolizumab and axitinib plus avelumab in [...]
Avelumab as a first- or second-line treatment for metastatic kidney cancer
A recent study looked at the efficacy and safety of [...]
Comparison of first-line immunotherapy combinations for advanced kidney cancer
In this paper, three clinical trials with immunotherapy combinations for [...]
European Commission approves avelumab plus axitinib combination for the first-line treatment of advanced kidney cancer
Based on the findings from the pivotal phase III JAVELIN [...]
ESMO 2019: Kidney cancer tumour shrinkage in patients who did not have surgery
This interview with Dr Monty Pal, Associate Professor from the [...]
ESMO 2019: First-line avelumab plus axitinib in sarcomatoid kidney cancer – results from JAVELIN Renal 101
Results from the JAVELIN Renal 101 study to evaluate avelumab [...]
ESMO 2019: Avelumab plus axitinib in patients who had not had nephrectomy
Results from a post-hoc analysis of JAVELIN-Renal 101 in patients [...]
ESMO 2019: Results from JAVELIN-Renal 101 trial for sarcomatoid kidney cancer
Results from the JAVELIN-Renal 101 clinical trial to assess avelumab [...]
European Medicines Agency approves avelumab plus axitinib for first-line treatment of advanced kidney cancer
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines [...]
Avelumab plus axitinib combination available via EAMS
It has just been announced that the avelumab plus axitinib [...]
